

REMARKS

Claims 1-25 are currently pending in this application. Claims 4, 10, 13-14 were withdrawn. Applicant requests that the previously withdrawn claims to additional non-elected species be allowed, because they depend from or otherwise require all the limitations of the allowable generic claim(s).

The Examiner stated in the Office Action mailed on March 18, 2011 that claims 1-25 will be allowed if amended to overcome the rejections under 35 U.S.C. 112.

Claim 1 has been amended to delete the term “terminal group” and to insert in its place the definitions of A and B, as originally recited in claims 2 and 3, respectively. Claim 1 also has been amended to recite the definition of Q, support for which may be found in the Specification, as originally filed, *inter alia* at paragraph [0035].

Claims 2 and 3 have been cancelled without prejudice.

Claim 4 has been amended to recite its dependency on claim 1 as a result of the cancellation of claim 2. Claims 5 and 19 have been amended to correctly recite the superscript of the R³ group and the subscript of the C₂-C₆, respectively. Claim 22 has been amended to depend upon claim 1, which provides antecedent basis for formula (I). Claims 18 and 20 have been amended to delete glycerol.

Claim 24 has been amended to add step (a) “applying to or printing onto a substrate an energy-curable composition according to Claim 23” before step (b) of “exposing the energy-curable composition to actinic radiation”. Support for amendment to claim 24 may be found in the Specification as originally filed *inter alia* at paragraphs [0002], which describes various ways of applying to and printing onto substrates the photocurable compositions of the invention, as well as at Example 13 in which inks comprising the exemplified sensitizers of Examples 3-11 were printed onto a substrate.

No new matter has been added. Accordingly, claims 1 and 4-25 will be pending.

Favorable reconsideration and allowance of the claims are earnestly solicited.

Rejection under 35 U.S.C. § 112, second paragraph

The Examiner has rejected claims 1-25 as allegedly being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention. Specifically, the Examiner states that the term “terminal group” (for A and B) in claim 1 is a relative term and that the term is not defined by the claims. Secondly, the Examiner also states that the term “residue” (for Q) in claim 1 and 17-20 renders the claim indefinite because ‘residue’ implies more than what is being positively recited. Thirdly, the Examiner rejects claim 24 as being incomplete for omitting essential steps, which amounts to a gap between the steps.

Without conceding the correctness of the Examiner’s rejections and solely to advance the prosecution of the subject application, Applicant has amended claim 1 to define A and B as recited in original claims 2 and 3; claim 1 also has been amended to define Q as “a residue of a C₂-C₆ polyalkylene glycol or is a bis(C₁-C₆ hydroxyalkyl) ether” as defined in the Specification, as originally filed, *inter alia* at paragraph [0035].

Applicant also has amended claim 24 to recite step (a) “applying or printing onto a substrate an energy-curable composition” before the previously recited step of “exposing” the energy-curable “composition according to claim 23 to actinic radiation” [which now is numbered as step (b)]. Accordingly, claim 24 is complete in its recitation of steps.

Applicant maintains that the pending claims particularly point out and distinctly claim the subject matter which applicant regards as the invention

Accordingly, Applicant respectfully requests withdrawal of the rejection of claims 1-25 under 35 U.S.C. § 112, second paragraph.

Conclusion

It is believed that no fee is required with the submission of this Amendment and Response to Office Action. However, if any additional fee is due, the Director is hereby authorized to charge any additional deficiencies or credit any overpayments to Deposit Account No. 50-0540.

Respectfully submitted,

Date: April 4, 2011

By: /Elizabeth M. Wieckowski/
Elizabeth M. Wieckowski, Reg. No. 42,226
Charles Achkar, Reg. No. 43,311
KRAMER LEVIN NAFTALIS & FRANKEL LLP
1177 Avenue of the Americas
New York, New York 10036
(212) 715-9100 Tel
(212) 715-8000 Fax